Davinderpreet Mangat
Advertisement
Latest From Davinderpreet Mangat
PARP Inhibitor Market Dynamics: A Podcast
Bookmark
-
Analysis
PARP inhibitors are expected to generate $10bn in sales by 2030. Datamonitor Healthcare analysts discuss their positioning in breast, ovarian, pancreatic and prostate cancer, looking at the current market landscape and future strategies.
Advertisement
Kevin Grogan
Email Author
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.